Colivelin prolongs survival of an ALS model mouse

Tomohiro Chiba, Marina Yamada, Jumpei Sasabe, Kenzo Terashita, Sadakazu Aiso, Masaaki Matsuoka, Ikuo Nishimoto

研究成果: Article

32 引用 (Scopus)

抜粋

Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease for which there is no sufficiently effective therapy. We have reported in our earlier study that intracerebroventricular (i.c.v.) injection of activity-dependent neurotrophic factor (ADNF) improves motor performance of G93A-SOD1 transgenic mice without significant prolongation in survival. Here, we found that i.c.v. injection of a synthetic hybrid peptide named Colivelin composed of ADNF and AGA-(C8R)HNG17, a potent derivative of Humanin that is a bioactive peptide with anti-Alzheimer's disease activity, dose-dependently improved motor performance and prolonged survival of ALS mice. Histological analysis, performed at the age of 120 days, demonstrated increased motoneuronal survival in spinal cords of Colivelin-treated mice as compared with saline- or ADNF-treated mice, indicating that Colivelin is a promising neurotrophic peptide for treatment of ALS.

元の言語English
ページ(範囲)793-798
ページ数6
ジャーナルBiochemical and Biophysical Research Communications
343
発行部数3
DOI
出版物ステータスPublished - 2006 5 12

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

フィンガープリント Colivelin prolongs survival of an ALS model mouse' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Chiba, T., Yamada, M., Sasabe, J., Terashita, K., Aiso, S., Matsuoka, M., & Nishimoto, I. (2006). Colivelin prolongs survival of an ALS model mouse. Biochemical and Biophysical Research Communications, 343(3), 793-798. https://doi.org/10.1016/j.bbrc.2006.02.184